Use The Force: St. Jude Hopes To Build AFib Footprint With Pressure-Sensing Catheter
This article was originally published in The Gray Sheet
The TactiCath Quartz irrigated ablation catheter, acquired in the Endosense deal in 2013, lets electrophysiologists monitor the force exerted by the catheter tip on the endocardium during an atrial fibrillation ablation procedure.
You may also be interested in...
The diversified company is entering the atrial fibrillation catheter ablation for the first time. It is acquiring Afib ablation mapping system maker Topera and has gained rights to buy catheter developer Advanced Cardiac Therapeutics.
St. Jude Medical has acquired Swiss company Endosense, a pioneer in the field of contact force sensing for atrial fibrillation ablation. The $170 million plus milestones deal will enable St. Jude to compete more effectively against market leader Biosense Webster/J&J, but it also emphasizes the growing importance of contact force technology in the AF ablation space.
The $170 million acquisition, plus milestones, gives St. Jude Medical access to contact-force-sensing catheter ablation technology, strengthening its cardiac ablation pipeline and offering opportunities to enhance currently marketed products.